Innovations in gene editing continue to expand functional capabilities. Korean researchers developed a dual-mode CRISPR system capable of simultaneous gene activation and repression, surpassing traditional CRISPR limitations and enabling complex synthetic biology applications. Revvity and Profluent announced a collaboration to develop an advanced base editing toolkit using AI-designed enzymes to enable precise single-nucleotide edits without bystander effects. Furthermore, studies reveal the structure of a compact Cas9d enzyme, promising a novel genome-editing platform with high efficacy. These advances may accelerate therapeutic development for genetic diseases.